India's Drug Regulator Waits for UK Move Before Nod to SII's COVID Vax

Drug regulatory body of India is looking at the UK's Medicines and Healthcare products Regulatory Agency (MHRA) approval to AstraZeneca/Oxford's COVID-19 vaccine before approving Emergency Use Authorisation (EUA) to its Indian counterpart developed by Serum Institute of India (SII).

The sources indicated that the Central Drugs Standard Control Organisation (CDSCO) would hold a meeting of its Subject Expert Committee (SEC) to review the safety and immunogenicity data of SII's Covishield once the MHRA gives the Oxford's Covid-19 vaccine the go-ahead. As per the English dailies of the UK, the drug regulatory body there is likely to approve Oxford's candidate before January 5.

Side Effects, Efficacy Reasons for COVID Vaccine Hesitancy in India: Study
Even as the Central government preps up to roll out the COVID-19 vaccination drive soon, about 60 percent of people are hesitant to take it due to the fear of side effects, efficacy, and reduction in cases, according to a new study.

‘Officials said both the Pfizer and the SII emergency use applications are being examined on an accelerated basis. But as the trials for Serum's Covishield are still ongoing in India, the UK regulator's lack of approval for the AstraZeneca shot might prove a hurdle. ’

Tweet it Now

However, the officials at the CDSCO did not comment on the information.

Meanwhile, AstraZeneca's Chief Executive Officer Pascal Soriot had stated a day ago that his vaccine candidate, who is co-developed with Jenners's Institute of the Oxford University, the company's coronavirus vaccine is 100 percent effective against the Covid-19 disease. He said the vaccine has a "winning formula" for efficacy.

Soriot had also hoped for approval from the MHRA by the end of the year.

Health Experts React To Russian Covid Vaccine Cautiously
Cautiously after the news of Russia registering the world's first Covid-19 vaccine, Indian health experts stressed that it would be too early to say if it is safe or not as adequate testing didn't take place.

The applications by three firms for EUA of their Covid vaccine are pending review at India's drug regulatory authority. Pfizer, SII, and Bharat Biotech had applied for the EUA to the Drug Controller General of India earlier this month. However, their applications were not approved as the SEC found inadequate safety and efficacy data of the vaccines in a review meeting held on December 9.

Pfizer was the first to apply for the EUA in India on December 5, followed by Pune-based SII on December 6. Bharat Biotech sought EUA for its Covid vaccine -- Covaxin -- on December 7.

Clinical Trials of Covid Vaccine Begins In India
For India's first indigenous Covid-19 vaccine, two volunteers were given its first dose at the Nizam's Institute of Medical Sciences (NIMS) on Monday.

While Pfizer sought more time from the SEC as its experts were busy and could not present their case on December 9, the SEC had asked SII and Bharat Biotech to furnish further safety and efficacy data to receive the EUA for their Covid vaccines.

The SEC had asked SII to submit an updated safety data of Phase 2 and 3 clinical trials in the country, immunogenicity data from the clinical trial in the UK and India, along with the outcome of the assessment by MHRA. While it had recommended Bharat Biotech to present the safety and efficacy data from the ongoing Phase 3 clinical trials in the country for further consideration.

COVID Vaccine Will be Ready by 'Start of Next Year' In India
Union Health Minister Harsh Vardhan on Thursday said that the coronavirus vaccine will be made available in the country by the start of next year.

IANS had reported a few days ago that the SII had submitted the additional data sought by the CDSCO.

Pfizer's vaccine has already been approved by several countries, including the UK, the US, and Bahrain. Meanwhile, the SII has already manufactured 40 million doses of its vaccine under the at-risk manufacturing and stockpiling license from the DCGI, the officials had informed recently.

Source-IANS